EQS-News: Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023


 

EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year Report
Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023

10.08.2023 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 10 August 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023. At € 10.9 million or € 0.52 per share, net income was € 3.5 million or 25% lower than in the same period last year. Currency effects in particular reduced the result by around € 2.0 million compared with the previous year. Moreover, increased expenses for future projects in the field of diagnostics and therapy in nuclear medicine had an additional impact.

In the Medical segment, sales in the first half of the year amounted to € 52.6 million, around € 11.1 million or 27% above the previous year's level. Main growth driver continued to be the business with pharmaceutical radioisotopes, with sales of laboratory equipment also continuing to increase.

The Isotope Products segment generated sales of € 65.3 million, € 0.6 million lower than in the first six months of 2022. Almost all main product groups remained stable, however, high-margin sales of radiation sources for applications in the energy sector recorded a weaker first half than in the previous year.

The forecast for the financial year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of just under € 230 million and net income of around € 25 million.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz223e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com 



10.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1700125

 
End of News EQS News Service

1700125  10.08.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1700125&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 138,63 168,71 178,49 176,14 180,44 222,26 246,09
EBITDA1,2 26,62 32,14 43,13 44,64 57,04 55,52 58,83
EBITDA-Marge3 19,20 19,05 24,16 25,34 31,61 24,98
EBIT1,4 17,97 23,39 32,06 33,69 47,45 44,54 45,45
EBIT-Marge5 12,96 13,86 17,96 19,13 26,30 20,04 18,47
Jahresüberschuss1 15,12 16,89 22,48 23,11 34,66 29,75 26,77
Netto-Marge6 10,91 10,01 12,59 13,12 19,21 13,39 10,88
Cashflow1,7 26,83 21,21 40,43 36,79 33,86 34,30 47,40
Ergebnis je Aktie8 0,70 0,78 1,07 1,11 1,66 1,41 1,26
Dividende8 0,20 0,30 0,42 0,45 0,50 0,50 0,17
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Forvis Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 45,860 Halten 970,94
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
28,66 26,56 1,05 48,30
KBV KCV KUV EV/EBITDA
4,39 20,49 3,95 15,98
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,50 0,05 0,11 18.06.2025
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
13.05.2025 09.08.2024 14.11.2024 27.03.2025
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
6,15% 8,44% 11,04% 42,87%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei EQS abrufen


Medtech , 565970 , EUZ , XETR:EUZ